Qi Y, Zhang S, Wang K, Ding H, Zhang Z, Anang S
Commun Biol. 2025; 8(1):442.
PMID: 40089599
DOI: 10.1038/s42003-025-07852-z.
Odidika S, Pirkl M, Lengauer T, Schommers P
Front Immunol. 2025; 15():1443377.
PMID: 39835119
PMC: 11743526.
DOI: 10.3389/fimmu.2024.1443377.
Lee M, Lu M, Zhang B, Zhou T, Katte R, Han Y
Comput Struct Biotechnol J. 2024; 23:4192-4204.
PMID: 39640534
PMC: 11617889.
DOI: 10.1016/j.csbj.2024.11.020.
Ding H, Nguyen H, Li W, Deshpande A, Zhang S, Jiang F
J Virol. 2024; 98(12):e0172024.
PMID: 39508605
PMC: 11650979.
DOI: 10.1128/jvi.01720-24.
Zhang Z, Anang S, Wang Q, Nguyen H, Chen H, Chiu T
bioRxiv. 2024; .
PMID: 39484577
PMC: 11527345.
DOI: 10.1101/2024.10.25.620268.
Computational design of prefusion-stabilized Herpesvirus gB trimers.
McCallum M, Veesler D
bioRxiv. 2024; .
PMID: 39484573
PMC: 11526958.
DOI: 10.1101/2024.10.23.619923.
The KT Jeang retrovirology prize 2024: Walther Mothes.
Mothes W
Retrovirology. 2024; 21(1):16.
PMID: 39449025
PMC: 11515334.
DOI: 10.1186/s12977-024-00649-8.
CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies.
Richard J, Sannier G, Zhu L, Prevost J, Marchitto L, Benlarbi M
mBio. 2024; 15(11):e0182724.
PMID: 39373535
PMC: 11559134.
DOI: 10.1128/mbio.01827-24.
Exploring HIV-1 Maturation: A New Frontier in Antiviral Development.
McGraw A, Hillmer G, Medehincu S, Hikichi Y, Gagliardi S, Narayan K
Viruses. 2024; 16(9).
PMID: 39339899
PMC: 11437483.
DOI: 10.3390/v16091423.
The asymmetric opening of HIV-1 Env by a potent CD4 mimetic enables anti-coreceptor binding site antibodies to mediate ADCC.
Richard J, Grunst M, Niu L, Diaz-Salinas M, Tolbert W, Marchitto L
bioRxiv. 2024; .
PMID: 39253431
PMC: 11383012.
DOI: 10.1101/2024.08.27.609961.
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity.
Marchitto L, Richard J, Prevost J, Tauzin A, Yang D, Chiu T
J Virol. 2024; 98(10):e0101624.
PMID: 39248460
PMC: 11495009.
DOI: 10.1128/jvi.01016-24.
Conformations of membrane human immunodeficiency virus (HIV-1) envelope glycoproteins solubilized in Amphipol A18 lipid-nanodiscs.
Zhang S, Anang S, Zhang Z, Nguyen H, Ding H, Kappes J
J Virol. 2024; 98(10):e0063124.
PMID: 39248459
PMC: 11495050.
DOI: 10.1128/jvi.00631-24.
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics.
Tauzin A, Marchitto L, Belanger E, Benlarbi M, Beaudoin-Bussieres G, Prevost J
J Virol. 2024; 98(10):e0096024.
PMID: 39230306
PMC: 11495032.
DOI: 10.1128/jvi.00960-24.
Conformational dynamics of the HIV-1 envelope glycoprotein from CRF01_AE is associated with susceptibility to antibody-dependent cellular cytotoxicity.
Diaz-Salinas M, Chatterjee D, Nayrac M, Medjahed H, Prevost J, Pazgier M
bioRxiv. 2024; .
PMID: 39229074
PMC: 11370484.
DOI: 10.1101/2024.08.22.609179.
HIV-1-envelope trimer transitions from prefusion-closed to CD4-bound-open conformations through an occluded-intermediate state.
Lee M, Lu M, Zhang B, Zhou T, Katte R, Han Y
bioRxiv. 2024; .
PMID: 39071380
PMC: 11275901.
DOI: 10.1101/2024.07.15.603531.
Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs.
Zhang Z, Anang S, Nguyen H, Fritschi C, Smith 3rd A, Sodroski J
iScience. 2024; 27(7):110141.
PMID: 38979012
PMC: 11228805.
DOI: 10.1016/j.isci.2024.110141.
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity.
Marchitto L, Richard J, Prevost J, Tauzin A, Yang D, Chiu T
bioRxiv. 2024; .
PMID: 38895270
PMC: 11185797.
DOI: 10.1101/2024.06.07.597978.
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in presence of CD4-mimetics.
Tauzin A, Marchitto L, Belanger E, Benlarbi M, Beaudoin-Bussieres G, Prevost J
medRxiv. 2024; .
PMID: 38883797
PMC: 11177920.
DOI: 10.1101/2024.06.02.24308281.
An HIV-1 broadly neutralizing antibody overcomes structural and dynamic variation through highly focused epitope targeting.
Hodge E, Chatterjee A, Chen C, Naika G, Laohajaratsang M, Prasad V
Npj Viruses. 2024; 1(1):2.
PMID: 38665238
PMC: 11041648.
DOI: 10.1038/s44298-023-00002-4.
Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors.
Hikichi Y, Grover J, Schafer A, Mothes W, Freed E
Sci Adv. 2024; 10(9):eadn0042.
PMID: 38427738
PMC: 10906922.
DOI: 10.1126/sciadv.adn0042.